Close Menu


Sermonix will launch the ELAINE-1 study at Exactis Innovation network sites across Canada to study the activity of its drug in ESR1-mutated breast cancer.

The firms will collaborate on identifying patients with NRG1 fusion-positive tumors and turn local cancer centers into study sites for the CRESTONE trial.

Sema4 will use its genomics testing abilities and Centrellis health intelligence platform to identify eligible patients for Janssen's oncology clinical trials.

Avapritinib is sold by Blueprint Medicines as Ayvakit for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.

The companies will explore the IDE196 and Xalkori combination in solid tumors with GNAQ or GNA11 mutations, such as metastatic uveal melanoma.

The company hopes the collaboration will allow it to home in on a molecularly defined population of patients likely to benefit from its targeted agent LP-184.

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.

The lab will use its GEM ExTra test to identify patients with NRG1 fusion-positive solid tumors who may be eligible to enroll in the Phase II CRESTONE trial.